Quick Answer
Quince Therapeutics, Inc. reported Stockholders Equity of $30.15 million for the year ending 2024.
- Quince Therapeutics, Inc. showed a decrease of -64.6% in Stockholders Equity from 2023 to 2024.
- This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$23.64 million | Q2 2018: -$26.74 million | Q3 2018: -$29.26 million | Q1 2019: -$38.03 million | Q2 2019: $136.22 million | Q3 2019: $127.29 million | Q1 2020: $218.04 million | Q2 2020: $205.47 million | Q3 2020: $188.01 million | Q1 2021: $156.48 million | Q2 2021: $142.08 million | Q3 2021: $132.65 million | Q1 2022: $106.38 million | Q2 2022: $111.53 million | Q3 2022: $104.53 million | Q1 2023: $90.20 million | Q2 2023: $86.88 million | Q3 2023: $83.13 million | Q4 2023: $85.08 million | Q1 2024: $74.18 million | Q2 2024: $46.97 million | Q3 2024: $44.93 million | Q4 2024: $30.15 million | Q1 2025: $18.58 million | Q2 2025: $11.74 million | Q3 2025: $1.06 million.
- Over the full 8 years of available data (2017 to 2024), Quince Therapeutics, Inc.'s Stockholders Equity has grown by 248.6%.
- Historical annual values: Fiscal year 2024: $30.15 million | Fiscal year 2023: $85.08 million | Fiscal year 2022: $100.59 million | Fiscal year 2021: $118.59 million | Fiscal year 2020: $172.26 million | Fiscal year 2019: $115.48 million | Fiscal year 2018: -$32.63 million | Fiscal year 2017: -$20.28 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: